Simona Degli Esposti

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 772 citations

Hematological Malignancy, Medicine, Pathology +6

Partial recovery of visual function in a blind patient after optogenetic therapy

José‐Alain Sahel, Élise Boulanger-Scemama, Chloé Pagot et al. · Nature Medicine · 2021 · 652 citations · Full text

Partial Recovery, Ophthalmology, Visual Impairment +12

A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema

Ranjan Rajendram, Samantha Fraser‐Bell, Andrew Kaines et al. · Archives of Ophthalmology · 2012 · 386 citations

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Asim V. Farooq, Simona Degli Esposti, Rakesh Popat et al. · Ophthalmology and Therapy · 2020 · 169 citations · Full text